About 2seventy Bio
2seventy bio focuses on developing new cancer therapies by combining knowledge of cancer cell biology, genetics, and the immune response. Their approach aims to create treatments that can significantly change how cancer is treated today. The company serves cancer patients, healthcare providers, and the medical community, generating revenue through research and development of novel therapies that undergo clinical trials and regulatory approval. What sets 2seventy bio apart from competitors is its commitment to rapidly advancing these therapies, reflecting its goal of giving patients more time to enjoy life.
Cambridge, MassachusettsHeadquarters
2021Year Founded
$165.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Risks
Increased competition from companies like Gilead Sciences and Novartis in CAR-T therapy.
Dependency on Abecma's success may limit diversification and financial stability.
Regulatory challenges and potential delays in FDA approval for new indications.
Differentiation
2seventy bio focuses on BCMA-targeted CAR T-cell therapy for multiple myeloma.
The company leverages deep knowledge of cancer cell biology and genetics.
2seventy bio collaborates with Bristol Myers Squibb for enhanced distribution and marketing.
Upsides
FDA approval of Abecma expands its use in multiple myeloma treatment.
Strategic realignment leads to significant financial savings and extended cash runway.
Partnership with Bristol Myers Squibb strengthens market presence and distribution.
Funding
Total raised$165.36 M
StageIPO
POST IPO EQUITY
1/31/2023$125
IPO
10/31/2021$34